Watch BCRX. Know when insiders buy.
One email the day a filing lands. Free.
BCRX
BIOCRYST PHARMACEUTICALS INC
7.78
+0.03 +0.39%
USD · close Oct 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
42
WATCH · shorts 42
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2BP/E —DIV YIELD —FCF YIELD 18.78%REV TTM —NET INCOME −$384.7MNET DEBT $143.2M52W 6.24 – 11.11SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | $98.5M | $78.4M | +1441.7% | 0.30 | $104.3M | $209K | $104.1M | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$701.6M | −$721.8M | −2255762.5% | -2.98 | −$61.8M | $403K | −$62.2M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | $260.4M | $245.8M | — | 1.13 | $292M | $802K | $291.2M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | $29.6M | $12.9M | — | 0.06 | $41.6M | $1.3M | $40.3M | Nov 4 |
| Q2 2025 · Jun 30 | — | — | — | $29.8M | $5.1M | — | 0.02 | $41.3M | $179K | $41.1M | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | $21.2M | $32K | — | 0.00 | −$27.5M | $143K | −$27.7M | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$4.5M | −$26.8M | — | -0.13 | −$5.2M | $675K | −$5.9M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | $7.7M | −$14M | — | -0.07 | $8.2M | $59K | $8.2M | Nov 4 |
| Q2 2024 · Jun 30 | — | — | — | $8.8M | −$12.7M | — | -0.06 | −$1.4M | $155K | −$1.5M | Nov 4 |
| Q1 2024 · Mar 31 | — | — | — | −$14.5M | −$35.4M | — | -0.17 | −$53.7M | $235K | −$53.9M | Nov 4 |
| Q4 2023 · Dec 31derived | — | — | — | −$42.7M | −$61.7M | — | -0.31 | −$8.9M | $554K | −$9.5M | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$11.9M | −$36.1M | — | -0.19 | −$19.9M | $987K | −$20.9M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | $341M | $263.9M | — | 1.21 | $347.4M | $2.5M | $344.9M | — | — |
| FY2024 · to Dec 31 | — | — | −$2.5M | −$88.9M | — | -0.43 | −$52M | $1.1M | −$53.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$103.7M | −$226.5M | — | -1.18 | −$95.1M | $2.2M | −$97.3M | — | — |
| FY2022 · to Dec 31 | — | — | −$148.4M | −$247.1M | — | -1.33 | −$161.8M | $1.4M | −$163.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$177.7M | −$184.1M | — | -1.03 | −$142.2M | $2.4M | −$144.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$174.8M | −$182.8M | — | -1.09 | −$135.1M | $514K | −$135.6M | — | — |
Every number comes from BIOCRYST PHARMACEUTICALS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.